FI117438B - Förfarande för framställning av optiskt anrikat bupivakain - Google Patents

Förfarande för framställning av optiskt anrikat bupivakain Download PDF

Info

Publication number
FI117438B
FI117438B FI971711A FI971711A FI117438B FI 117438 B FI117438 B FI 117438B FI 971711 A FI971711 A FI 971711A FI 971711 A FI971711 A FI 971711A FI 117438 B FI117438 B FI 117438B
Authority
FI
Finland
Prior art keywords
bupivacaine
water
optically enriched
tartaric acid
levobupivacaine
Prior art date
Application number
FI971711A
Other languages
English (en)
Finnish (fi)
Other versions
FI971711A0 (sv
FI971711A (sv
Inventor
Marianne Langston
Benjamin Mark Skead
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421476A external-priority patent/GB9421476D0/en
Priority claimed from GBGB9504926.8A external-priority patent/GB9504926D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of FI971711A0 publication Critical patent/FI971711A0/sv
Publication of FI971711A publication Critical patent/FI971711A/sv
Application granted granted Critical
Publication of FI117438B publication Critical patent/FI117438B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)

Claims (8)

1. Förfarande för framställning av optiskt anrikat t bupivakain, vid vilket förfarande bupivakainet bringas att 5 reagera med ett vinsyra-resolveringsmedel i ett med vatten j blandbart organiskt lösningsmedium, kanne tecknat av att mediet innehäller 1 - 20 % vatten.
2. Förfarande enligt patentkrav 1, känneteck-nat av att mängden resolveringsmedel är under 0,5 ekviva- 10 lenter per en molekvivalent bupivakain.
3. Förfarande enligt patentkrav 2, kanne tee k-nat av att mängden resolveringsmedel är 0,2 - 0,5 molek-vivalenter per en molekvivalent bupivakain.
4. Förfarande enligt nägot av de föregäende pa-15 tentkraven, kännetecknat av att resolveringsmedlet är (S, S)-vinsyra.
5. Förfarande enligt nägot av de föregäende pa-tentkraven, kännetecknat av att lösningsmedlet omfat- tar en C; ,,-alkanol. . , ' : 20
6. Förfarande enligt nägot av de föregäende pa- tentkraven, kännetecknat av att mediet innehäller 1 - 5. vatten. d tttm·
7. Förfarande enligt nägot av de föregäende pa- • · . tentkraven, kännetecknat av att det ytterligare om- ;i ,, * 25 fattar konversion av det optiskt anrikade bupivakainet ; " tili ett hydrokloridsalt.
* * 8. Förfarande enligt nägot av de föregäende pa- ·* :’·* tentkraven, kännetecknat av att man framställer levo- • · · ί.ί ί bupivakain. • · · • · · ΐ • · ♦ • · • · • · · • · · » · • · ' • ♦ · • · ... • » ...··* • · · • ·· • · ’ V • ♦ *·* ··*·· • * .
FI971711A 1994-10-25 1997-04-22 Förfarande för framställning av optiskt anrikat bupivakain FI117438B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9421476A GB9421476D0 (en) 1994-10-25 1994-10-25 Process and salt
GB9421476 1994-10-25
GB9504926 1995-03-10
GBGB9504926.8A GB9504926D0 (en) 1995-03-10 1995-03-10 Crystallisation
PCT/GB1995/002513 WO1996012699A1 (en) 1994-10-25 1995-10-23 Crystallisation of levobupivacaine and analogues thereof
GB9502513 1995-10-23

Publications (3)

Publication Number Publication Date
FI971711A0 FI971711A0 (sv) 1997-04-22
FI971711A FI971711A (sv) 1997-04-22
FI117438B true FI117438B (sv) 2006-10-13

Family

ID=26305863

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971711A FI117438B (sv) 1994-10-25 1997-04-22 Förfarande för framställning av optiskt anrikat bupivakain

Country Status (16)

Country Link
US (1) US5994548A (sv)
EP (1) EP0788480B1 (sv)
JP (1) JP3911545B2 (sv)
AT (1) ATE245629T1 (sv)
AU (1) AU698637B2 (sv)
CA (1) CA2200355C (sv)
DE (1) DE69531356T2 (sv)
DK (1) DK0788480T3 (sv)
ES (1) ES2202375T3 (sv)
FI (1) FI117438B (sv)
HU (1) HU227420B1 (sv)
MX (1) MX9703024A (sv)
NO (1) NO309266B1 (sv)
PL (1) PL183210B1 (sv)
PT (1) PT788480E (sv)
WO (1) WO1996012699A1 (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0002246A (pt) * 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
BRPI0104491B8 (pt) * 2001-10-10 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda n-(2,6-dimetilfenil)-1-propil-2-piperidinocarboxamida; processo de obtenção dos enantiômeros; mistura não racêmica dos anantiômeros e seu processo de obtenção e composição farmacêutica.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
US7094812B2 (en) * 2003-04-24 2006-08-22 Xerox Corporations Colorant compositions
US6790267B1 (en) * 2003-04-24 2004-09-14 Xerox Corporation Colorant compositions
SI2767292T1 (sl) 2004-09-17 2017-01-31 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP2010491A1 (en) * 2006-04-25 2009-01-07 Disham Pharmaceuticals and Chemicals Ltd. Ropivacaine hydrochloride anhydrate and the preparation thereof
ES2388355T3 (es) 2006-11-03 2012-10-11 Durect Corporation Sistemas de suministro transdémico que comprenden bupivacaína
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
PT2234974E (pt) * 2008-01-15 2012-05-29 Pharmathen Sa Processo para a preparação do composto (s)-l-alquil-2',6'- pipecoloxilidida
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN103073484B (zh) * 2013-01-28 2014-10-22 山东诚创医药技术开发有限公司 一种甲哌卡因及其光学对映体的制备方法
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US11000487B2 (en) * 2016-12-26 2021-05-11 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE341404B (sv) * 1967-05-18 1971-12-27 Sterling Drug Inc
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide

Also Published As

Publication number Publication date
ATE245629T1 (de) 2003-08-15
NO971903D0 (no) 1997-04-24
JPH10507464A (ja) 1998-07-21
US5994548A (en) 1999-11-30
NO309266B1 (no) 2001-01-08
PT788480E (pt) 2003-12-31
DE69531356D1 (de) 2003-08-28
WO1996012699A1 (en) 1996-05-02
FI971711A0 (sv) 1997-04-22
CA2200355C (en) 2007-03-06
EP0788480A1 (en) 1997-08-13
HUT77631A (hu) 1998-06-29
DE69531356T2 (de) 2004-05-27
AU3704895A (en) 1996-05-15
EP0788480B1 (en) 2003-07-23
PL183210B1 (pl) 2002-06-28
PL319829A1 (en) 1997-09-01
NO971903L (no) 1997-04-24
AU698637B2 (en) 1998-11-05
DK0788480T3 (da) 2003-09-29
JP3911545B2 (ja) 2007-05-09
HU227420B1 (en) 2011-05-30
MX9703024A (es) 1997-10-31
ES2202375T3 (es) 2004-04-01
FI971711A (sv) 1997-04-22
CA2200355A1 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
FI117438B (sv) Förfarande för framställning av optiskt anrikat bupivakain
RU2009128C1 (ru) Гидрохлориды производных 1-бензил-4[(1-инданон)]-метилпиперидина
US20060276654A1 (en) Process of making optically pure L-pipecolic acid and process of making anesthetics and intermediates therefrom
JP4015696B2 (ja) レボブピバカインと同類のピペリジンカルボキサニリド麻酔剤の製造に用いるラセミ化法
WO2016038422A1 (en) Process for the preparation of optically enriched adrenaline
AU696875B2 (en) New process for the preparation of ropivacaine hydrochloride monohydrate
US20110065755A1 (en) Stable r(+)-lansoprazole amine salt and a process for preparing the same
DE3625738A1 (de) 2-acyloxypropylamin-derivate, verfahren zu deren herstellung und deren verwendung
US6521792B2 (en) Process for separating the diastereomeric bases of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-cylohexanol
DK152752B (da) Fremgangsmaade til fremstilling af l-sulpirid
EP3074397B1 (en) A process for preparation of (2s, 5r)-7-oxo-n-[(2s)-pyrrolidin-2-yl-methyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
DK1988086T4 (en) Method of dissolving citalopram via its (S) -riched citalopram tartrate compound
US20080167470A1 (en) Process of enantiomeric resolution of D,L-(+_)-threo-methylphenidate
KR100472609B1 (ko) 레보부피바카인과그의유사체의결정화벙법
US5929242A (en) Manufacture of levobupivacaine and analogues thereof from L-lysine
JPH1036327A (ja) １−（３−メトキシフェニル）エチルアミンの光学活性体の製造方法
JPS6383056A (ja) ジアステレオマーの分割
JPH08245530A (ja) 光学活性ｔ−ロイシノールの製造方法、４−ｔ−ブチル−２−オキサゾリジノン、オキサゾリン、二環式ラクタム、メルカプトフェニルオキサゾリン、ビスオキサコリンまたはビス（オキサゾリニル）ピリジンの製造方法、医薬または植物保護における有効物質の非対称的合成法および製造方法、および新規化合物
US20080171885A1 (en) Process for Preparation of Highly Pure Trandolapril
WO1990002732A1 (en) Methods for preparing captopril and its analogues
JPS61268633A (ja) ラセミ有機アミンの光学分割方法
WO1990002118A1 (en) Derivatives and precursors of captopril and its analogues
JPH05255243A (ja) アジリジン−２−カルボン酸誘導体及びその製造方法
MXPA97008494A (en) New process for the preparation of clorhidratode ropivacain monohidrat
HU207831B (en) Process for producing enanthiomere mixtures of nitrogen-containing bases dividing raceme composition

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117438

Country of ref document: FI

MA Patent expired